 |
424 Diseases |  |
809 Trials |
|
809 Trials |  |
14393 News |  |
| «12...6970717273747576777879...235236» |
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date, Trial primary completion date: AALL1731: A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 1, 2022
P3, N=6720, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Mar 2028 --> Sep 2029 | Trial primary completion date: Mar 2028 --> Sep 2029
- ||| spevatamig (PT886) / Phanes Therap
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date, Checkpoint inhibition: Spevatamig (PT886) for Treatment of Patients with Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study) (clinicaltrials.gov) - Dec 1, 2022
P1, N=58, Recruiting, Sponsor: Phanes Therapeutics
Trial completion date: Mar 2028 --> Sep 2029 | Trial primary completion date: Mar 2028 --> Sep 2029 Not yet recruiting --> Recruiting | Trial completion date: Jan 2024 --> Apr 2024 | Initiation date: Aug 2022 --> Nov 2022 | Trial primary completion date: Aug 2023 --> Nov 2023
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
If you had someone responding to FOLFIRINOX at 4 months of chemo. Would you stop it? If no. Then this trial may not be relevant to your practice. (Twitter) - Nov 30, 2022
- ||||| Retrospective data, Review: Different neoadjuvant therapies for locally advanced rectal cancer: A systematic review and network meta-analysis 87% probability of best regimen👇 FOLFIRINOX➡️Capecitabine-based RT @CHematology #rectalcancer https://t.co/dgLChDqUZ6 (Twitter) - Nov 30, 2022
- | methotrexate / Generic mfg.
Journal: Methotrexate-induced acute cardiotoxicity requiring veno-arterial extracorporeal membrane oxygenation support: a case report. (Pubmed Central) - Nov 30, 2022
After a process of elimination, the most likely cause of this patient's acute decline and rapid recovery of bi-ventricular function was methotrexate toxicity. Leucovorin may have aided the reversal of methotrexate toxicity.
- | leucovorin calcium / Generic mfg.
Journal: Spiro heterocycles bearing piperidine moiety as potential scaffold for antileishmanial activity: synthesis, biological evaluation, and in silico studies. (Pubmed Central) - Nov 30, 2022
Furthermore, the antileishmanial activity reversal of these compounds via folic and folinic acids displayed comparable results to the positive control trimethoprim...Moreover, the docking experiments of 8a and 9a against Lm-PTR1 rationalised the observed in vitro activities. Molecular dynamics simulations confirmed a stable and high potential binding to Lm-PTR1.
- ||| 5-fluorouracil / Generic mfg.
Review, Journal, Adverse events: Coriolus (Trametes) versicolor mushroom to reduce adverse effects from chemotherapy or radiotherapy in people with colorectal cancer. (Pubmed Central) - Nov 30, 2022
While there was low-certainty evidence of a small effect on overall survival at five years, the influence of reduced adverse effects on this could not be determined. In addition, chemotherapy regimens used in assessing this outcome do not reflect current preferred practice.
- Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
Second-Line and Third-Line Therapy with Nanoliposomal Irinotecan (nal-IRI) in pancreatic cancer: A Single Center Experience () - Nov 30, 2022 - Abstract #DKK2022DKK_2356;
In this setting, first-line palliative therapies with FOLFIRINOX or gemcitabine/nab-paclitaxel have been established in the last decade... Nal-IRI + 5-FU/LV may be considered for patients with advanced PC, even after prior nonliposomal irinotecan therapy.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Treatment Patterns in Patients with BRAF V600E mutant metastatic colorectal carcinoma: German and Austrian Subgroups from the CAPSTAN CRC retrospective study (Room A2) - Nov 30, 2022 - Abstract #DKK2022DKK_2294;
CT + anti EGFR (cetuximab or panitumumab) was used in 9% of pts in D. Median duration of 1 st -line treatment was 4.7 and 2.2 months (D/A)... In line with updated DGHO guideline recommendations, doublet CT was used as the preferred backbone for anti-VEGF treatment.
- A Lesson from Lynch Syndrome: Five-Year Survival of a Patient with Metastatic Pancreatic Cancer, Post Ovarian and Breast Cancer and MLH1 Heterozygosity () - Nov 30, 2022 - Abstract #DKK2022DKK_2262;
Our patient had atypical LS with MLH1 heterozygosity but MSS. Therefore, immune checkpoint inhibitor therapy was not recommended and the patient had excellent response to chemotherapy and radiotherapy.
- 5-fluorouracil / Generic mfg.
Impact of the sequence of modern combination chemotherapy protocols on survival of patients with advanced pancreatic cancer treated at the West German Cancer Center Essen () - Nov 30, 2022 - Abstract #DKK2022DKK_2238;
In clinical studies modern combination therapy protocols such as FOLFIRINOX or gemcitabine/nab-paclitaxel (G/nP) demonstrated superior survival outcomes over monochemotherapies... The choice of first-line chemotherapy, FOLFIRINOX or G/nP, had no impact on survival outcomes of this real-world cohort of PDAC patients.
- 5-fluorouracil / Generic mfg., irinotecan / Generic mfg.
Remarkable tumor response after addition of epidermal growth factor receptor monoclonal antibody therapy combined with irinotecan based chemotherapy in patient with primary chemotherapy resistant metastatic colorectal cancer with KRAS G13D mutation – A case report (Room A2) - Nov 30, 2022 - Abstract #DKK2022DKK_2217;
It seems remarkable that in primary chemotherapy-resistant mCRC with KRAS G13D mutation simply by switching antibody therapy, tumor response could be achieved. Switching antibody therapy may be considered for 2 nd line treatment.
- Lynparza (olaparib) / Merck (MSD), AstraZeneca
Long-term survival of a patient with metastatic and recurrent pancreatic acinar cell carcinoma harboring somatic BRCA1/2 variants of unknown significance treated with Olaparib maintenance therapy following local treatment () - Nov 30, 2022 - Abstract #DKK2022DKK_2134;
He received a 12 cycles FOLFIRINOX achieving partial remission, followed by FOLFIRI maintenance therapy (15 cycles)...Gemcitabine/nab-paclitaxel failed to stop progression... In our patient with a chemo-resistant PACC, harboring somatic BRCA1/2 variants of unknown significance, Olaparib mainte- nance therapy following local ablative procedures was feasible and con- tributed to an excellent survival benefit.
- Pemazyre (pemigatinib) / Incyte, Specialised Therap
Global Expanded Access Program (EAP) to pemigatinib for patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA) and FGFR2 fusions or rearrangements () - Nov 30, 2022 - Abstract #DKK2022DKK_2006;
A total of 79 pts received PEMI from 68 physicians through the EAP from January 2020 to June 2021 (Europe, 86.1%; Canada, 8.9%; USA, 3.8%; Israel, 1.3%; median age, 61 years [IQR, 48–67]; women, 67.1%; ≥1 reported prior therapy, 89.9%, most commonly cisplatin-gemcitabine [41.8%] and FOLFIRI [8.9%])... The results indicate that pts with CCA should receive molec- ular testing to identify eligible pts who might benefit from PEMI.
- Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
Outcomes of patients with locally advanced or metastatic pancreatic cancer treated with different sequential treatment strategies –data from the prospective Tumour Registry Pancreatic Cancer () - Nov 30, 2022 - Abstract #DKK2022DKK_1967;
Patients starting with FFX are younger. However, outcome data on PFS2 and OS are comparable in all those pts.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
RAS mutant metastatic colorectal cancer – Real-world data from more than 1000 patients from the Clinical Tumor Registry Colorectal Cancer (TKK) (Room A2) - Nov 30, 2022 - Abstract #DKK2022DKK_1959;
Guidelines recommend chemotherapy (CT; fluoropyrimidine, irinotecan, oxaliplatin) with/without anti-angio- genic agents for two treatment lines...The percent- age of pts receiving 3 rd -line trifluridine/tipiracil increased from 9% in 2016 to 38% in 2019. This analysis of the RAS mut mCRC population enrolled prospectively in the TKK database provides important insights into treat- ment patterns, sequential treatments, and outcome of patients with RAS mut mCRC in routine clinical practice in Germany.
- Multicentric validation of a comprehensive geriatric assessment to predict functional outcome and mortality following urooncological operations (Room A2) - Nov 30, 2022 - Abstract #DKK2022DKK_1955;
Background: Fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) regimen has shown strong efficacy as perioperative therapy for patients with locally advanced gastric (GC) and gastroesophageal (AEG) carcinoma. In palliative situation FLOT displays an efficient treatment option for patients with a good ECOG performance status and should therefore be considered in the therapeutic decision making of elderly patients with GC and AEG.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Preoperative chemoradiotherapy (preopCRT) for locally advanced rectal cancer (LARC) - a benefit for all? - the view of a study site (Room A2) - Nov 30, 2022 - Abstract #DKK2022DKK_1887;
In palliative situation FLOT displays an efficient treatment option for patients with a good ECOG performance status and should therefore be considered in the therapeutic decision making of elderly patients with GC and AEG. PreopCRT + OX resulted in better survival in stage ≤ II cancer ( II were identified as «non-responders».
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Adjuvant FOLFOX (adCTx) in cancer of the upper rectum (≥ 12 cm above AV) after upfront surgery – single-center experience (Room A2) - Nov 30, 2022 - Abstract #DKK2022DKK_1886;
PreopCRT + OX resulted in better survival in stage ≤ II cancer ( II were identified as «non-responders». mFOLFOX improves survival in patients with stage III upper rectal cancer.
- oxaliplatin / Generic mfg.
Role of oxaliplatin in multimodality treatment (MMT) of rectal cancer – a single center experience (Room A2) - Nov 30, 2022 - Abstract #DKK2022DKK_1845;
OX in MMT is safe, feasible, and leads to improved early tumor regression, esp. In TNT, associated with good compliance and Survival.
- Avastin (bevacizumab) / Roche
Survival of patients (pts) with BRAF V600E mutated metastatic colorectal cancer (mCRC) treated with systemic therapy in a real-world setting (Room A2) - Nov 30, 2022 - Abstract #DKK2022DKK_1791;
Intensive 1st-line therapy has no impact on OS. The implementation of moABX and BRAFi during therapy correlates with prolonged OS.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Effectiveness of a Video Sequence Based Intervention on Anxiety, Fatigue and Depression in Cancer Patients (Room A2) - Nov 30, 2022 - Abstract #DKK2022DKK_1713;
represent a clinically significant, yet very heterogenous subgroup. Since the demand for cancer treatment for elderly patients will increase within the next decades RWD will be an important source for tailoring optimized treatment.
- Multicenter randomized phase III study of 5‐FU, leucovorin, oxaliplatin, and doxetaxel (FLOT) versus epirubicin, cisplatin, and 5‐FU (ECF) in patients with locally advanced resectable adenocarcinoma of the esophagogastric junction and stomach (Room M8) - Nov 30, 2022 - Abstract #DKK2022DKK_1486;
- Opdivo (nivolumab) / Ono Pharma, BMS
Posterior Reversible Encephalopathy Syndrome: A Rare Side Effect of Nivolumab () - Nov 29, 2022 - Abstract #ASH2022ASH_7828;
He was started on steroids along with 500 mg Keppra twice a day...He was discharged and started on Fluorouracil, Folinic Acid, Oxaliplatin (FOLFOX) chemotherapy as outpatient for possible upper gastrointestinal (GI) cancer...He was started on a high dose of prednisone, 1mg/kg/day along with 20 mg lisinopril for strict blood pressure control with a goal of 120/80 mmHg...Recommendations are to avoid fluctuations in blood pressure with a goal of 130-150/80-100mmHg. If any triggering factor or condition is identified like immunotherapy, it should be avoided or treated accordingly.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
P2 data, Journal: Study protocol for HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibodies. (Pubmed Central) - Nov 29, 2022
FOLFIRI (irinotecan 180 mg/m, l-leucovorin 200 mg/m, bolus 5-FU 400 mg/m, and infusional 5-FU 2400 mg/m/46 h) and AFL (4 mg/kg) will be administered every 2 weeks until progression or unacceptable toxicities occur...Japan Registry of Clinical Trials, jRCTs011190006. Registered 19 November, 2019, https://jrct.niph.go.jp/latest-detail/jRCTs011190006.
- |||| botensilimab (AGEN1181) / Agenus
New P2 trial: A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Nov 29, 2022
P2, N=78, Not yet recruiting, Sponsor: Agenus Inc.
- ||||| Clinical: 🔥WJOG13219G: FOLFOXIRI or Doublet + anti-VEGF in mBRAF V600E #ColonCancer 🔥 in Clinical Colorectal Cancer https://t.co/AluySAnMC7 🔎BRACELET study, RWD 180 pts 👉Triplet group was younger & better ECOG, but no OS benefit 🧐Role for conversion to surgery? @myESMO @OncoAlert (Twitter) - Nov 28, 2022
- | Avastin (bevacizumab) / Roche
Enrollment change: Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer (clinicaltrials.gov) - Nov 28, 2022
P1, N=11, Active, not recruiting, Sponsor: City of Hope Medical Center
Registered 19 November, 2019, https://jrct.niph.go.jp/latest-detail/jRCTs011190006. N=30 --> 11
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
New P2 trial: TORCH-R: The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer (clinicaltrials.gov) - Nov 28, 2022
P2, N=75, Not yet recruiting, Sponsor: Fudan University
- ||| Lonsurf (trifluridine/tipiracil) / Otsuka, Opdivo (nivolumab) / BMS
Enrollment open: LOGICAN: Oxaliplatin (clinicaltrials.gov) - Nov 28, 2022
P2, N=118, Recruiting, Sponsor: UNICANCER
N=30 --> 11 Not yet recruiting --> Recruiting
- || Imfinzi (durvalumab) / AstraZeneca
Review, Journal: Gallbladder Cancer: Current Multimodality Treatment Concepts and Future Directions. (Pubmed Central) - Nov 27, 2022
Recent advances with the PD-L1 inhibitor durvalumab open the therapy landscape for immune checkpoint inhibition in GBC. Meanwhile, targeted therapy approaches are a cornerstone of GBC therapy based on molecular profiling and new evidence of molecular differences between different BTC forms and might further improve the prognosis of GBC patients.
- || MT-5745 / Mitsubishi Tanabe, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
P1/2 data, Journal: STNM01, the RNA oligonucleotide targeting carbohydrate sulfotransferase 15, as second-line therapy for chemotherapy-refractory patients with unresectable pancreatic cancer: An open label, phase I/IIa trial. (Pubmed Central) - Nov 26, 2022
This was an open-label, dose-escalation study of STNM01 as second-line therapy in gemcitabine plus nab-paclitaxel-refractory PDAC...It prolonged survival by enhancing T cell infiltration in tumor microenvironment. The present study was supported by the Japan Agency for Medical Research and Development (AMED).
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: Über 4,5 Monate erhält die Patientin eine Chemotherapie (9x FOLFOX). Danach wird das Rektumkarzinom. bestrahlt (5x5 Gy). Normalerweise würde sich in dieser Situation eine Operation anschließen und angesichts der Beteiligung ein künstlicher Darmausgang (Stoma) notwendig werden. (Twitter) - Nov 25, 2022
- ||||| E7820 / Eisai
Trial termination, Metastases: Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer (clinicaltrials.gov) - Nov 25, 2022
P1/2, N=82, Terminated, Sponsor: Eisai Inc.
The present study was supported by the Japan Agency for Medical Research and Development (AMED). Completed --> Terminated; The study was terminated by the Sponsor due to E7820 plus irinotecan being potentially inferior to FOLFIRI
- | Avastin (bevacizumab) / Roche, botensilimab (AGEN1181) / Agenus, balstilimab (AGEN2034) / Agenus
New P1/2 trial: NCI-2022-09458: FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer (clinicaltrials.gov) - Nov 25, 2022
P1/2, N=86, Not yet recruiting, Sponsor: City of Hope Medical Center
- | Opdivo (nivolumab) / BMS, Stivarga (regorafenib) / Bayer
Enrollment closed, Trial completion date, Trial primary completion date: A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer (clinicaltrials.gov) - Nov 25, 2022
P2, N=39, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Completed --> Terminated; The study was terminated by the Sponsor due to E7820 plus irinotecan being potentially inferior to FOLFIRI Recruiting --> Active, not recruiting | Trial completion date: Feb 2023 --> Feb 2024 | Trial primary completion date: Feb 2023 --> Feb 2024
- | Avastin (bevacizumab) / Roche
Journal: Heterotopic ossification in primary rectal cancer with squamous cell carcinoma-like differentiation. (Pubmed Central) - Nov 24, 2022
She received chemotherapy (mFOLFOX6 with bevacizumab) as the first option and is alive 5 months after surgery...This case suggests that BMP-2 transformed fibroblasts and pluripotent stem cells into osteocytes. We conclude that the squamous cell carcinoma-like lesion was squamous metaplasia of adenocarcinoma.
- | 5-fluorouracil / Generic mfg.
Journal: Evaluation of Adjuvant Chemotherapy Survival Outcomes Among Patients With Surgically Resected Pancreatic Carcinoma With Node-Negative Disease After Neoadjuvant Therapy. (Pubmed Central) - Nov 24, 2022
Adjuvant therapy consisted of gemcitabine-based therapy or FOLFIRINOX; when used, adjuvant radiation was commonly administered as either SBRT or IMRT...The findings of this cohort study suggest a survival benefit for AT in patients with N0 disease after NAT and surgical resection. This survival benefit may be most pronounced in patients with PNI.
- ||||| Clinical: Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial @JAMAOnc @SWOG @DavendraSohal @rachnatshroff @CathyEngMD https://t.co/NVkjy3NymO (Twitter) - Nov 24, 2022
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Journal: A Case of Ascending Colon Cancer Metastasis to Right External Iliac Lymph Nodes (Pubmed Central) - Nov 23, 2022
This rare occurrence highlights the importance of examining adjacent lymph nodes for possible tumor recurrence. We report this case with the necessary literature review.
- || Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
P2 data, Journal: Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial. (Pubmed Central) - Nov 23, 2022
We explored safety profile of nal-IRI combination regimen recognized as effective and tolerable treatment for Japanese unresectable pancreatic cancer patients. Although the treatment-emergent adverse events occurred were controllable, patients with prolonged toxicities should be closely managed.
- ||| etrumadenant (AB928) / Arcus Biosci, Gilead, quemliclustat (AB680) / Arcus Biosci, Gilead
Enrollment closed, Metastases: ARC-9: An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. (clinicaltrials.gov) - Nov 23, 2022
P1b/2, N=227, Active, not recruiting, Sponsor: Arcus Biosciences, Inc.
Although the treatment-emergent adverse events occurred were controllable, patients with prolonged toxicities should be closely managed. Recruiting --> Active, not recruiting
- |||| Clinical: Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer https://t.co/umPK7rIK8Y a través de @JAMAOnc part of @JAMANetwork (Twitter) - Nov 22, 2022
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Retrospective data, Journal: The efficacy and safety of modified FOLFIRINOX for unresectable advanced pancreatic cancer in elderly versus young patients: A multicenter retrospective cohort study. (Pubmed Central) - Nov 22, 2022
First-line mFX for APC in elderly patients was as safe and effective as in younger patients if performance status was good. Further evaluation in a larger cohort is required to confirm our findings.
- |||| Clinical: Adding zolbetuximab (a novel drug created by @AstellasUS) to the chemotherapy regimen of oxaliplatin, leucovorin and fluorouracil improved outcomes for patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma, explained @KoheiShitara. https://t.co/LORyyyj2qI (Twitter) - Nov 22, 2022
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal: Neo-adjuvant FOLFIRINOX in borderline resectable and locally advanced pancreatic adenocarcinoma. (Pubmed Central) - Nov 22, 2022
Neoadjuvant FOLFIRINOX is an active regimen for patients with LA/BR PDAC with a resection rate of 22.5%. These results are in line with prior data.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Journal: Circulating DNA in the neoadjuvant setting of early stage colon cancer. (Pubmed Central) - Nov 22, 2022
This is the first study of ctDNA in the neoadjuvant setting of early-stage colon cancer. Results are hypothesis-generating and should be confirmed in larger series.
- || Clinical, Journal: Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. (Pubmed Central) - Nov 22, 2022
P3
The final 5-year results from the PRODIGE 24/Canadian Cancer Trials Group PA6 randomized clinical trial indicate that adjuvant treatment with modified FOLFIRINOX yields significantly longer survival than gemcitabine in patients with resected pancreatic ductal adenocarcinoma. EudraCT: 2011-002026-52; ClinicalTrials.gov Identifier: NCT01526135.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Journal, HEOR: Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial. (Pubmed Central) - Nov 22, 2022
P3
EudraCT: 2011-002026-52; ClinicalTrials.gov Identifier: NCT01526135. This analysis showed encorafenib with cetuximab to be a cost-effective treatment in mCRC patients with a BRAF V600E mutation.
- | Trial completion, Trial primary completion date: Supportive Oncology Care at Home for Patients With Pancreatic Cancer Receiving Preoperative FOLFIRINOX (clinicaltrials.gov) - Nov 22, 2022
P=N/A, N=60, Completed, Sponsor: Massachusetts General Hospital
This analysis showed encorafenib with cetuximab to be a cost-effective treatment in mCRC patients with a BRAF V600E mutation. Active, not recruiting --> Completed | Trial primary completion date: Sep 2022 --> Jun 2022